HNSBF (Hansa Biopharma AB) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HNSBF Hansa Biopharma AB HNSBF
42 GF Score
Price $2.90
GF Value $1.64
! 7 Warning Signs
View Full Analysis

What is Hansa Biopharma AB FFO per Share?

FFO per Share only applies to REITs.

HNSBF
42GF Score
Hansa Biopharma AB HNSBF
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Hansa Biopharma AB (HNSBF) Overvalued in 2026?

Based on GuruFocus' analysis, Hansa Biopharma AB stock appears to be overvalued. The current stock price of $2.90 is trading 76.8% above its estimated GF Value™ of $1.64.

Key valuation signals for HNSBF:

  • FFO per Share:
  • GF Value™: $1.64 vs. price of $2.90 (76.8% above fair value)
  • GF Score™: 42/100 with 7 warning signs

No single metric tells the full story. See the HNSBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Hansa Biopharma AB Business Description

Address Scheelevagen 22, Lund, SWE, 223 63
Hansa Biopharma AB is a commercial-stage biopharmaceutical company pioneering the development and commercialization of life-saving and life-altering therapies for patients with rare immunological conditions. It has developed a proprietary, first-in-class antibody-cleaving enzyme technology platform designed to eliminate pathogenic IgG antibodies. This differentiated platform supports a broad pipeline with potential applications across Transplantation, Autoimmune diseases, and Gene Therapy-areas characterized by unmet medical need. Hansa's first-generation IgG-cleaving enzyme, imlifidase, is designed to inactivate all four IgG subclasses (IgG1, IgG2, IgG3, and IgG4) in both the intravascular and extravascular compartments following a single intravenous administration.
42GF Score

Get the complete analysis for HNSBF

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.90
Price
$1.64
GF Value